Parabilis Medicines charts $413M IPO to back peptide pipeline
Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with its plans, that ...
Mathai Mammen, Parabilis Medicines CEO (via Sandoz) June 4, 2026 09:04 AM EDT DealsIPOs Parabilis Medicines charts $413M IPO to back peptide pipeline Kyle LaHucik Biotech Correspondent Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that